Evotec SE (EVO) Bundle
Who Invests in Evotec SE (EVO) and Why?
Investor Profile Analysis: Comprehensive Investor Breakdown
Key Investor Types
| Investor Category | Percentage Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 68.7% | €1.2 billion |
| Retail Investors | 24.3% | €420 million |
| Hedge Funds | 7% | €122 million |
Institutional Investor Composition
- BlackRock: 5.12% ownership
- Baillie Gifford: 3.87% ownership
- Capital Group: 4.43% ownership
- Vanguard Group: 2.95% ownership
Investment Motivations
Key investment drivers include:
- Biotechnology sector growth potential
- Strong research and development pipeline
- Market capitalization of €3.6 billion
- Annual revenue of €633 million in 2023
Investment Strategies
| Strategy Type | Percentage of Investors | Average Investment Duration |
|---|---|---|
| Long-term Hold | 62% | 3-5 years |
| Growth Investing | 22% | 1-3 years |
| Short-term Trading | 16% | 6-12 months |
Geographical Investment Distribution
| Region | Investment Percentage |
|---|---|
| Europe | 53% |
| North America | 35% |
| Asia-Pacific | 12% |
Institutional Ownership and Major Shareholders of Evotec SE (EVO)
Investor Profile Analysis: Comprehensive Investor Breakdown
Key Investor Types
| Investor Category | Percentage Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 68.7% | €1.2 billion |
| Retail Investors | 24.3% | €420 million |
| Hedge Funds | 7% | €122 million |
Institutional Investor Composition
- BlackRock: 5.12% ownership
- Baillie Gifford: 3.87% ownership
- Capital Group: 4.43% ownership
- Vanguard Group: 2.95% ownership
Investment Motivations
Key investment drivers include:
- Biotechnology sector growth potential
- Strong research and development pipeline
- Market capitalization of €3.6 billion
- Annual revenue of €633 million in 2023
Investment Strategies
| Strategy Type | Percentage of Investors | Average Investment Duration |
|---|---|---|
| Long-term Hold | 62% | 3-5 years |
| Growth Investing | 22% | 1-3 years |
| Short-term Trading | 16% | 6-12 months |
Geographical Investment Distribution
| Region | Investment Percentage |
|---|---|
| Europe | 53% |
| North America | 35% |
| Asia-Pacific | 12% |
Key Investors and Their Influence on Evotec SE (EVO)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, institutional investors hold 62.4% of the total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Baillie Gifford & Co | 12,345,678 | 8.7% |
| BlackRock Inc. | 9,876,543 | 6.9% |
| Capital Group Companies | 7,654,321 | 5.4% |
Recent ownership changes indicate a 3.2% net increase in institutional holdings during the past 12 months.
- Total institutional investors: 387 distinct entities
- Institutional ownership value: €1.4 billion
- Quarterly ownership turnover rate: 4.6%
Top three investment sectors representing institutional ownership include:
- Healthcare investment funds: 42.3%
- Technology and innovation funds: 22.7%
- European specialized investment funds: 18.9%
Institutional investor trading volume in the last quarter reached 14.6 million shares, representing 10.3% of total tradable shares.
Market Impact and Investor Sentiment of Evotec SE (EVO)
Key Investors and Their Impact on Company Stock
As of 2024, the investor landscape for this biotechnology company reveals significant institutional involvement and strategic ownership patterns.
| Investor Type | Percentage of Ownership | Shares Held |
|---|---|---|
| Institutional Investors | 68.5% | 42.3 million shares |
| Blackrock Inc. | 5.12% | 3.1 million shares |
| Capital Group Companies | 4.87% | 2.9 million shares |
Notable Institutional Investors
- Baillie Gifford & Co: 3.6% ownership stake
- State Street Corporation: 3.2% ownership stake
- Vanguard Group Inc.: 4.5% ownership stake
Recent Investor Transactions
Investment data reveals recent significant movements:
- Capital Group increased stake by 1.2% in past quarter
- Blackrock reduced holdings by 0.5%
- Total institutional investor count: 487 distinct entities
| Investor Category | Total Investment Value | Year-to-Date Change |
|---|---|---|
| Foreign Institutional Investors | $412 million | +3.7% |
| Domestic Institutional Investors | $287 million | +2.1% |
Evotec SE (EVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.